TIMP1 and colorectal carcinoma: An increase in expression of TIMP metallopeptidase inhibitor 1 mRNA in platelets of CRC patients has a much higher receiver operating characteristic curve (0.958; 95% confidence interval [CI], 0.936–0.980) than CEA (0.765; 95% CI, N/A) and CA19-9 (0.612; 95% CI, N/A), indicating that the expression of TIMP metallopeptidase inhibitor 1 mRNA in platelets could be used as a non-invasive biomarker (37).